Compare Stocks: INFA, EPP, HGEN, and AMPH

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.13 +2.1%	$20.99	$16.65 ▼ $29.52	$1.03B	0.92	513,204 shs	175,235 shs
EPP iShares MSCI Pacific ex Japan ETF	$55.37 -1.0%	$56.68	$48.93 ▼ $58.56	$2.18B	0.78	396,842 shs	116,333 shs
INFA Informatica	$24.79	$24.81	$17.61 ▼ $24.98	$7.64B	N/A	3.67 million shs	N/A

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-1.13%	+3.10%	+13.06%	+21.79%	-13.31%
EPP iShares MSCI Pacific ex Japan ETF	-0.82%	-3.30%	-1.96%	+3.67%	+6.17%
INFA Informatica	0.00%	0.00%	0.00%	0.00%	+0.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$24.13 +2.1%	$20.99	$16.65 ▼ $29.52	$1.03B	0.92	513,204 shs	175,235 shs
EPP iShares MSCI Pacific ex Japan ETF	$55.37 -1.0%	$56.68	$48.93 ▼ $58.56	$2.18B	0.78	396,842 shs	116,333 shs
INFA Informatica	$24.79	$24.81	$17.61 ▼ $24.98	$7.64B	N/A	3.67 million shs	N/A

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-1.13%	+3.10%	+13.06%	+21.79%	-13.31%
EPP iShares MSCI Pacific ex Japan ETF	-0.82%	-3.30%	-1.96%	+3.67%	+6.17%
INFA Informatica	0.00%	0.00%	0.00%	0.00%	+0.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	1.75	Reduce	$22.50	-6.75% Downside
EPP iShares MSCI Pacific ex Japan ETF	2.79	Moderate Buy	$55.64	0.49% Upside
INFA Informatica	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest INFA, EPP, HGEN, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	AMPH Amphastar Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$20.00 ➝ $23.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$21.00 ➝ $20.00
8/7/2026	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$19.00 ➝ $20.00
7/21/2026	AMPH Amphastar Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/8/2026	AMPH Amphastar Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
6/29/2026	AMPH Amphastar Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral ➝ Underperform	$25.00 ➝ $20.00
6/22/2026	AMPH Amphastar Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$719.89M	1.43	$4.29 per share	5.62	$17.17 per share	1.41
EPP iShares MSCI Pacific ex Japan ETF	N/A	N/A	N/A	N/A	N/A	N/A
INFA Informatica	$1.64B	4.66	N/A	N/A	$6.64 per share	3.73

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$98.09M	$1.69	14.34	9.32	4.61	10.76%	14.98%	6.96%	11/5/2026 (Estimated)
EPP iShares MSCI Pacific ex Japan ETF	N/A	N/A	18.02	N/A	N/A	N/A	N/A	N/A	N/A
INFA Informatica	$9.93M	$0.02	1,240.12	35.93	N/A	0.62%	5.51%	2.48%	N/A

Latest INFA, EPP, HGEN, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2026	Q2 2026	AMPH Amphastar Pharmaceuticals	$0.62	$0.91	+$0.29	$0.67	$179.92 million	$183.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EPP iShares MSCI Pacific ex Japan ETF	$1.87	3.38%	N/A	N/A	N/A
INFA Informatica	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.79	2.40	1.71
EPP iShares MSCI Pacific ex Japan ETF	N/A	N/A	N/A
INFA Informatica	0.73	2.16	2.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
EPP iShares MSCI Pacific ex Japan ETF	74.75%
INFA Informatica	98.45%

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	29.60%
EPP iShares MSCI Pacific ex Japan ETF	N/A
INFA Informatica	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	1,976	42.54 million	29.95 million	Optionable
EPP iShares MSCI Pacific ex Japan ETF	N/A	39.30 million	N/A	Not Optionable
INFA Informatica	5,200	308.36 million	299.73 million	Optionable

INFA, EPP, HGEN, and AMPH Headlines

Recent News About These Companies

Ex-Informatica CISO Roger Hale Joins 1Kosmos as Chief Information Security Officer

June 23, 2026 | globenewswire.com

Like DoorDash and Google’s CEOs, $7.6 billion Informatica boss is a McKinsey alum—he says being ‘pushed around’ by smart consultants helped him grow

January 17, 2026 | fortune.com

Informatica Named a Leader in 2026 Gartner® Magic Quadrant™ for Data & Analytics Governance Platforms

January 9, 2026 | businesswire.com

Informatica Inc. (NYSE:INFA) Receives Average Rating of â€œReduceâ€ from Brokerages

December 26, 2025 | defenseworld.netD

Informatica Named a Leader in 2025 Gartner® Magic Quadrant™ for Data Integration Tools for 20 Consecutive Years

December 11, 2025 | businesswire.com

Investigation Launched into Informatica Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD Law

December 10, 2025 | markets.businessinsider.com

Investigation Launched into Informatica Inc., Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - RGRD Law

December 10, 2025 | newsfilecorp.comN

Why the timing was right for Salesforce’s $8 billion acquisition of Informatica — and for the opportunities ahead

December 6, 2025 | fortune.com

Salesforce Beats, Raises Outlook — With Informatica Deal Adding Boost

December 5, 2025 | investors.com

Salesforce beats, raises outlook — with Informatica deal adding spark

December 4, 2025 | msn.com

Informatica Named a Leader in the 2025 Gartner® Magic Quadrant™ for Metadata Management Solutions Report

November 21, 2025 | businesswire.com

Analysts Offer Insights on Technology Companies: IonQ (IONQ) and Informatica (INFA)

November 20, 2025 | theglobeandmail.com

Informatica Terminates Credit Agreement Amidst Corporate Changes

November 18, 2025 | tipranks.com

Salesforce’s Strategic Acquisition of Informatica: Enhancing Data Management and AI Capabilities

November 18, 2025 | tipranks.com

Salesforce Completes Acquisition of Informatica

November 18, 2025 | tipranks.com

Salesforce Buys Informatica as Clean Data Becomes the Key to Winning the AI Race

November 18, 2025 | tipranks.com

STNE vs. INFA: Which Stock Is the Better Value Option?

November 14, 2025 | zacks.com

Salesforce (NYSE:CRM) to Acquire Spindle AI in Push for Smarter, Autonomous Enterprise Software

November 10, 2025 | msn.com

A Fresh Look at Informatica (INFA) Valuation as Shares Tread Water

November 9, 2025 | finance.yahoo.com

Informatica’s Strong Q3 2025 Financial Performance

November 5, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

INFA, EPP, HGEN, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$24.13 +0.49 (+2.06%)

As of 02:33 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

iShares MSCI Pacific ex Japan ETF NYSEARCA:EPP

$55.36 -0.57 (-1.01%)

As of 02:33 PM Eastern

iShares MSCI Pacific ex Japan ET (the Fund), formerly iShares MSCI Pacific ex-Japan Index Fund, is an exchange-traded fund (ETF). The Fund seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Australia, Hong Kong, New Zealand and Singapore markets, as measured by the MSCI Pacific ex-Japan Index (the Index). The Fund invests in a representative sample of securities that collectively has an investment profile similar to the underlying index. The securities selected are expected to have, in aggregate , investment characteristics, fundamental characteristics and liquidity measures similar to those of the underlying index. The Fund's investment advisor is BlackRock Fund Advisors.

Informatica NYSE:INFA

Informatica Inc. develops an artificial intelligence-powered platform that connects, manages, and unifies data across multi-vendor, multi-cloud, and hybrid systems at enterprise scale worldwide. Its platform includes a suite of interoperable data management products, including data integration products to ingest, transform, and integrate data; API and application integration products that enable users to create and manage APIs and integration processes for app-to-app synchronization, business process orchestration, B2B partner management, application development, and API management; data quality and observability products to profile, cleanse, standardize, observe, and monitor data to deliver accurate, complete, and consistent data; and master data management products to create an authoritative single source of truth of business-critical data. The company's platform also includes customer and business 360 application that allow business analysts to create 360-degree views of business data domains like customer, product, supplier, reference, and finance with simplified business user experiences; data catalog products that enables customers to quickly find, access, and understand enterprise data using a simple Google-like search experience; governance and privacy products that help users define policies, govern data, and ensure compliance with industry and corporate policies; and a data marketplace that delivers cloud shopping experience for data consumers and enables data sharing and AI models across organizations to facilitate data-driven decision making. It also offers maintenance and professional services. The company sells its products through its direct sales team. The company was founded in 1993 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INFA, EPP, HGEN, and AMPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INFA, EPP, HGEN, and AMPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INFA, EPP, HGEN, and AMPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INFA, EPP, HGEN, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

iShares MSCI Pacific ex Japan ETF NYSEARCA:EPP

Informatica NYSE:INFA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest INFA, EPP, HGEN, and AMPH Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest INFA, EPP, HGEN, and AMPH Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

INFA, EPP, HGEN, and AMPH Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

INFA, EPP, HGEN, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

iShares MSCI Pacific ex Japan ETF NYSEARCA:EPP

Informatica NYSE:INFA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools